FindTrial
Sign In

Morph 60 Study

A retrospective, single-center, observational study to assess the safety and performance of BioMime Morph Sirolimus Eluting Coronary Stent System in patients with Coronary Heart Diseases. - IIT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/04/085082
Enrollment
60
Registered
2025-04-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I00-I99- Diseases of the circulatory system

Interventions

Intervention1: Nil: Nil

Sponsors

Meril Life Sciences Indian Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with coronary heart disease who were implanted with 60 mm of BioMime Morph SES System

Exclusion criteria

Exclusion criteria: As this is a retrospective study, there are no formal exclusion criteria for the study

Design outcomes

Primary

MeasureTime frame
Target Lesion Failure (TLF) -Defined as the composite of cardiovascular death, target vessel myocardial infarction (TV-MI) and target lesion revascularization (TLR) Timepoint: Through 1 Year—

Secondary

MeasureTime frame
Cardiovascular deathTimepoint: Through 1 Year;Target Vessel Myocardial Infarction (TV-MI)Timepoint: Through 1 Year;Target Lesion Revascularization (TLR)Timepoint: Through 1 Year;Target Vessel Failure (TVF)Timepoint: Through 1 Year;Target Vessel Revascularization (TVR)Timepoint: Through 1 Year;Stent thrombosisTimepoint: Through 1 Year;StrokeTimepoint: Through 1 Year;Procedure successTimepoint: At Discharge;Device successTimepoint: During Procedure—

Countries

India

Contacts

Public ContactDr Pushpraj Patel

Golden Heart Hospital

dr.pushprajpatel@gmail.com9584024074

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026